Browse Category

FDA Updates News 16 December 2025 - 22 December 2025

Johnson & Johnson Stock (JNJ) Before the Market Opens on December 22, 2025: FDA Catalysts, Talc Litigation Headlines, Analyst Targets, and What to Watch

Johnson & Johnson Stock (JNJ) Before the Market Opens on December 22, 2025: FDA Catalysts, Talc Litigation Headlines, Analyst Targets, and What to Watch

Johnson & Johnson (NYSE: JNJ) heads into the U.S. market open on Monday, December 22, 2025, with investors balancing a familiar mix of defensive-healthcare appeal and headline-driven catalysts—from fresh talc litigation verdicts to FDA-related momentum in oncology and MedTech. Below
Philip Morris International (PM) Stock Week Ahead: Dividend Watch, FDA Nicotine Pouch Developments, Analyst Targets and Key Catalysts for Dec. 22–26, 2025

Philip Morris International (PM) Stock Week Ahead: Dividend Watch, FDA Nicotine Pouch Developments, Analyst Targets and Key Catalysts for Dec. 22–26, 2025

Published: Sunday, Dec. 21, 2025 (week-ahead outlook) Philip Morris International Inc. (NYSE: PM) heads into the Christmas-shortened trading week with a familiar mix of forces: a defensive consumer-staples profile, an income-driven shareholder base watching the next dividend milestone, and an
Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine, Inc. (NASDAQ: IRON) stock is seeing a classic “biotech catalyst storm” on Dec. 20, 2025: big intraday swings, headline-driven volatility, and analysts arguing over whether the market is repricing risk or merely repricing uncertainty. As of the latest
Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck & Co., Inc. (NYSE: MRK) finished Friday’s regular session (Dec. 19, 2025) modestly higher, then eased slightly in after-hours trading as investors digested a headline-heavy day featuring U.S. drug-pricing policy moves and FDA acceleration for two major Merck pipeline
Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals Limited (ASX:TLX, Nasdaq:TLX) entered the spotlight again on December 17, 2025, as TLX stock extended its December sell-off amid a fast-moving mix of clinical-trial updates, regulatory overhang, and investor litigation headlines. Telix Pharmaceuticals On the ASX, Telix shares
Go toTop